Dr Reddy’s Laboratories announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the US Food and Drug Administration (USFDA).

Capecitabine tablet is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:

Adjuvant Colon Cancer

– Patients with Dukes’ C colon cancer

Metastatic Colorectal Cancer

– First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred

Metastatic Breast Cancer

– In combination with docetaxel after failure of prior anthracycline-containing therapy

– As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen

The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.

Dr Reddy’s Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.